scorecardresearch
Add as a preferred source on Google
Wednesday, November 12, 2025
TopicIndia pharma industry

Topic: india pharma industry

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.

Why Trump’s executive order lowering prescription drug prices won’t rattle Indian pharma industry

The order aims to slash drug prices by up to 80%. Indian industry had been on edge since March amid threats of reciprocal tariff on pharmaceutical products.

How reciprocal Trump tariffs may impact Indian pharma, and become a bitter pill for the US

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, with chunk of their earnings hinging on exports to the country.

Hyderabad will be India’s life sciences capital, says CM Reddy as BioAsia 2025 kicks off

Telangana CM says his government will create 'pharma villages', potentially creating over 5 lakh jobs, and is also considering a dedicated life sciences policy.

24 mega-seller drugs set to lose patents in US, big opportunity for Indian drugmakers — govt report

Patent expiry would mean that drugmakers will be able to launch generic versions of the blockbuster drugs, which are typically priced up to 90 percent lower than their innovator drug.

No conferences in foreign locales, no gifts or hospitality — govt’s new marketing code for drugmakers

Uniform Code for Pharmaceutical Marketing Practices 2024, which replaces a 2015 code, remains voluntary, with its implementation watched by ethics panel constituted by pharma associations.

‘Can hamper entry of new drugs’ — groups raise alarm over IP proposals part of India-EFTA talks

India & EFTA (Iceland, Liechtenstein, Norway and Switzerland) are negotiating Trade and Economic Partnership Agreement (TEPA) that is likely to be finalized within next few weeks.

‘Adulterated drugs’ to breakthrough cancer therapy — how India’s health & pharma sector fared in 2023

The year was eventful with National Medical Commission's flip-flops over controversial decisions, tightening of various norms and launch of made-in-India drugs to treat rare diseases.

Indian pharma market can more than treble by 2030, says industry report, urges focus on quality

Report by Organisation of Pharmaceutical Producers of India and Ernst & Young says growth could be propelled by expansion in the domestic market, spurred by India's economic growth.

70% of antibiotic fixed-dose combination drugs sold in India unapproved or banned, finds study

Govt’s moves to curb irrational fixed-dose combinations may have been insufficient & lack enforcement, say researchers. Study published in Journal of Pharmaceutical Policy and Practice.

On Camera

This era has made journalistic independence harder than ever: New York Times publisher

Journalist Arthur Gregg Sulzberger delivered the Reuters Memorial Lecture on 4 March last year.

India’s factory data may get reality check in MoSPI’s new IIP plan, defunct factories to be dropped

MoSPI proposes to remove closed factories from IIP sample, aiming for truer picture of India’s industrial health in upcoming 2022–23 base series. Plan open to public feedback until 25 November.

‘Let them see’: Putin says new nuclear-powered missiles in the making, in message to Washington

At a ceremony felicitating Russian military engineers, Putin highlights Moscow’s 'parity' in defence technologies for the next century.

Bihar is where politics moves, and everything else stands still

Bihar is blessed with a land more fertile for revolutions than any in India. Why has it fallen so far behind then? Constant obsession with politics is at the root of its destruction.